Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease
Tenofovir alafenamide fumarate (TAF) was shown equally efficacious in suppressing hepatitis B virus (HBV) but with less renal toxicity than tenofovir disoproxil fumarate (TDF). The aim of this real-world study was to evaluate renal function in post-liver transplantation (LT) patients that changed TDF with TAF. Click here to read the article
Λεπτομέρειες